In vitro susceptibility of breakthrough Candida bloodstream isolates correlates with daily and cumulative doses of fluconazole

被引：33

作者：

Clancy, Cornelius J.

Staley, Benjamin

Nguyen, M. Hong

机构：

[1] Univ Florida, Coll Med, Dept Med, Gainesville, FL 32610 USA

[2] N Florida S Georgia Vet Hlth Syst, Gainesville, FL USA

[3] Univ Florida, Shands Teaching Hosp, Dept Pharm, Gainesville, FL USA

来源：

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY | 2006年 / 50卷 / 10期

关键词：

D O I：

10.1128/AAC.00741-06

中图分类号：

Q93 [微生物学];

学科分类号：

071005 ; 100705 ;

摘要：

We determined MICs for 28 Candida isolates recovered from patients who developed breakthrough candidemia while receiving fluconazole. MICs correlated with daily and cumulative doses of fluconazole. Patients receiving >= 2,000 mg cumulatively or > 200 mg daily were more likely to be infected with isolates that were not fluconazole susceptible.

引用

收藏

页码：3496 / 3498

页数：3

相关论文

共 20 条

[1] Fluconazole MIC and the fluconazole dose/MIC ratio correlate with therapeutic response among patients with candidemia [J].

Clancy, CJ ;

Yu, VL ;

Morris, AJ ;

Snydman, DR ;

Nguyen, MH .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2005, 49 (08) :3171-3177

[2] Rising incidence of Candida parapsilosis fungemia in patients with hematologic malignancies: Clinical aspects, predisposing factors, and differential pathogenicity of the causative strains [J].

Girmenia, C ;

Martino, P ;

DeBernardis, F ;

Gentile, G ;

Boccanera, M ;

Monaco, M ;

Antonucci, G ;

Cassone, A .

CLINICAL INFECTIOUS DISEASES, 1996, 23 (03) :506-514

[3] A CONTROLLED TRIAL OF FLUCONAZOLE TO PREVENT FUNGAL-INFECTIONS IN PATIENTS UNDERGOING BONE-MARROW TRANSPLANTATION [J].

GOODMAN, JL ;

WINSTON, DJ ;

GREENFIELD, RA ;

CHANDRASEKAR, PH ;

FOX, B ;

KAIZER, H ;

SHADDUCK, RK ;

SHEA, TC ;

STIFF, P ;

FRIEDMAN, DJ ;

POWDERLY, WG ;

SILBER, JL ;

HOROWITZ, H ;

LICHTIN, A ;

WOLFF, SN ;

MANGAN, KF ;

SILVER, SM ;

WEISDORF, D ;

HO, WG ;

GILBERT, G ;

BUELL, D .

NEW ENGLAND JOURNAL OF MEDICINE, 1992, 326 (13) :845-851

[4] Candidemia in allogeneic blood and marrow transplant recipients: Evolution of risk factors after the adoption of prophylactic fluconazole [J].

Marr, KA ;

Seidel, K ;

White, TC ;

Bowden, RA .

JOURNAL OF INFECTIOUS DISEASES, 2000, 181 (01) :309-316

[5] Development of fluconazole resistance in Candida albicans causing disseminated infection in a patient undergoing marrow transplantation [J].

Marr, KA ;

White, TC ;

vanBurik, JAH ;

Bowden, RA .

CLINICAL INFECTIOUS DISEASES, 1997, 25 (04) :908-910

[6] Myelofibrosis complicated by infection due to Candida albicans:: Emergence of resistance to antifungal agents during therapy [J].

Mori, T ;

Matsumura, M ;

Kanamaru, Y ;

Miyano, S ;

Hishikawa, T ;

Irie, S ;

Oshimi, K ;

Saikawa, T ;

Oguri, T .

CLINICAL INFECTIOUS DISEASES, 1997, 25 (06) :1470-1471

[7]

Myoken Y, 2004, HAEMATOLOGICA, V89, P378

[8]

Nguyen MH, 1996, AM J MED, V100, P617, DOI 10.1016/S0002-9343(95)00010-0

[9] Isolation and characterization of fluconazole- and amphotericin B-resistant Candida albicans from blood of two patients with leukemia [J].

Nolte, FS ;

Parkinson, T ;

Falconer, DJ ;

Dix, S ;

Williams, J ;

Gilmore, C ;

Geller, R ;

Wingard, JR .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1997, 41 (01) :196-199

[10] Risk factors for breakthrough candidemia [J].

Nucci, M ;

Colombo, AL .

EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 2002, 21 (03) :209-211